This is the first product launch under the previously announced exclusive licensing agreement between Nevakar Injectables, and Endo's subsidiary, Endo Ventures.
The Food and Drug Administration has approved Keytruda, Merck's anti-PD-1 therapy, as a single agent for the treatment of some patients with advanced endometrial carcinoma.
Through a partnership with RxRevu, FDB Vela brings real-time pharmacy benefit information to e-prescribing workflows embedded seamlessly within an EHR.
